The Epidemiology of SARS-CoV-2 Delta Variant in Kurdistan Region/Iraq

Main Article Content

Akam Mustafa Hasan
Zhian Salah Ramzi
Aram Mohammed Bra


The epidemiological characteristics of patients who infected with delta SARS-CoV-2 variant was studied in Kurdistan Region of Iraq.  A cross-sectional study has been carried out among positive patients of SARS-CoV-2 to compare Alpha, Delta and Omicron variants. The Alpha group included 1050 positive subjects diagnosed between June 10 and July 21, 2021, and 9505 patients diagnosed with delta variant enrolled to this study between July 20 August and December 10, 2021, Omicron variant enrolled 1418 cases between 20th December of 2021 to 30th of 2022. A descriptive statistics of the three groups' included the clinical and demographic featureof participants. Delta group had a significantly higher percent of patients with severe and moderate symptoms in comparison to the Alpha group (P value <0.05). Among vaccinated individuals, the percentage of symptomatic patients was higher in Delta group compared to Alpha and Omicron group. Odds ratios of symptomatic patients infected with delta variant was 3.08 (95% CI, 2.55–3.72) and it was1.10 (95% CI, 0.80–1.41) for hospitalization. Vaccination rate improvement of COVID-19 is considered as main concern to reduce the impacts of the virus on patients’ outcome. Additional strategies, such as social distancing, outdoor masking could be crucial in limiting the spread covid-19  infection.

Article Details

How to Cite
Akam Mustafa Hasan, Zhian Salah Ramzi, & Aram Mohammed Bra. (2023). The Epidemiology of SARS-CoV-2 Delta Variant in Kurdistan Region/Iraq. Journal of Coastal Life Medicine, 11(2), 1398–1404. Retrieved from


World Health Organization (WHO). Tracking SARS-CoV-2 Variants. Available online: tracking-SARS-CoV-2-variants/ (accessed on 20 January 2021).

Twohig, K.A.; Nyberg, T.; Zaidi, A.; Thelwall, S et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: A cohort study. Lancet Infect. Dis. 2021.

Bilgin S, Kurtkulagi O, Kahveci GB, Duman TT, Tel BMA. Millennium pandemic: a review of coronavirus disease (COVID-19). Exp Biomed Res. (2020) 3:117–25.

COVID C, Team R. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. (2020) 69:343–6.

Balkhair AA. COVID-19 pandemic:A new chapter in the history of infectious diseases. Oman Med J. 2020;35:e12

Faris L, Hiba R, Hanan K, Sinan G.M. Firas A, Yousef S. K, Riyadh A.A , Asaad L. M, Sundarasen S, Chinna K et al. Iraq experience in handling the COVID-19 pandemic: implications of public health challenges and lessons learned for future epidemic preparedness planning. Journal of Public Health, Volume 43, Issue Supplement_3, December 2021, Pages iii19–iii28.

PongpirulA, Pongpirul K, Ratnarathon AC, Prasithsirikul W. Journey of a Thai taxi driver and novel coronavirus. N Engl J Med. (2020) 382:1067–8.

Russell, T.W.; Golding, N.; Hellewell, J.; Abbott, S.; Wright, L.; Pearson, C.A.; van Zandvoort, K.; Jarvis, C.I.; Gibbs, H.; Liu, Y.; et al. Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections. BMC Med. 2020, 18, 1–9.

Pullano, G.; Di Domenico, L.; Sabbatini, C.E.; Valdano, E.; Turbelin, C.; Debin, M.; Guerrisi, C.; Kengne-Kuetche, C.; Souty, C.; Hanslik, T.; et al. Underdetection of cases of COVID-19 in France threatens epidemic control. Nature 2021, 590, 134–139

Yang, J.; Chen, X.; Deng, X.; Chen, Z et al. Disease burden and clinical severity of the first pandemic wave of COVID-19 in Wuhan, China. Nat. Commun. 2020, 11, 5411.

Budd, J.; Miller, B.S.; Manning, E.M et al. Digital technologies in the public-health response. Nat. Med. 2020, 26, 1183–1192.

Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020;5(11):1403-7.

Lustig, Y.; Zuckerman, N.; Nemet, Iet al. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Euro. Surveill. 2021, 26, 2100557.

Singh, J.; Rahman, S.A.; Ehtesham, N.Z.; Hira, S.; Hasnain, S.E. SARS-CoV-2 variants of concern are emerging in India. Nat. Med. 2021, 27, 1131–1133.

Callaway, E. Delta coronavirus variant: Scientists brace for impact. Nature 2021, 595, 17–18.

Mary Van Beusekom | News Writer | CIDRAP News | Jun 17, 2021. (2021, June 17). Youth, Delta variant behind UK covid surge. CIDRAP. Retrieved July 22, 2022, from

Liu, C. Ginn, H.M. Dejnirattisai, W. Supasa, P.; Wang, B. Tuekprakhon, A. Nutalai, R. Zhou, D. Mentzer, A.J. Zhao, Y. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 2021, 184, 4220–4236.e13.

Seppälä, E. Veneti, L. Starrfelt, J. Danielsen, A.S. Bragstad, K. Hungnes, O. Taxt, A.M. Watle, S.V. Meijerink, H. Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021. Euro. Surveill. 2021, 26, 2100793.

Lopez, J.; Andrews, N.; Gower, C.; Gallagher, E.; Simmons, R.; Thelwall, S.; Stowe, J.; Tessier, E.; Groves, N.; Dabrera, G.; et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 2021, 385, 585–594.

Adam, S. L. associate professor1, Mark, W.T. James, D. C. Clinical Severity of and effectiveness of mRNA vaccines against omicron, delta and alpha SARS-CoV-2 variants in the united states: Prospective and observational study. BMJ. 2022; 376.

Sonabend, R.; Whittles, L.K.; Imai, N.; Perez-Guzman, P.N.; Knock, E.S.; Rawson, T.; Gaythorpe, K.A.M.; Djaafara, B.A.; Hinsley, W.; FitzJohn, R.G.; et al. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: A mathematical modelling study. Lancet 2021, 398, 1825–1835.

Abbreviations:VOC: variant of conver, WHO: World Health Organization, CDC: center of disease control.